Meloxicam/rizatriptan, sold under the brand name Symbravo, is a fixed-dose combination medication used for the treatment of migraine. It is a combination of meloxicam, a nonsteroidal anti-inflammatory medication; and rizatriptan (as rizatriptan benzoate), a serotonin (5-HT) 1B/1D receptor agonist (triptan). The ratio in Symbravo is 20 mg meloxicam to 10 mg rizatriptan. It is taken by mouth.
Meloxicam/rizatriptan was approved for medical use in the United States in January 2025.
Medical uses.
Meloxicam/rizatriptan is indicated for the acute treatment of migraine with or without aura in adults.
Society and culture.
Legal status.
Meloxicam/rizatriptan was approved for medical use in the United States in January 2025.